Puretech Health Stock Price, News & Analysis

PureTech Health plc (Nasdaq: PRTC) announced its financial results for the year ending December 31, 2020, along with its cash balance as of March 31, 2021. The report highlights the company's commitment to developing innovative therapies for serious diseases. With a focus on clinical-stage biotherapeutics, PureTech aims to enhance patient outcomes through its advanced pharmaceutical solutions. The full financial details are accessible via the SEC's Form 20-F and on the company’s investor relations website.

PureTech Health (Nasdaq: PRTC) presented promising preclinical results for its LYT-210 antibody at the 2021 AACR Annual Virtual Meeting. The research shows LYT-210 is a highly specific and potent fully human monoclonal antibody targeting γδ1 T cells, which suppress the anti-tumor immune response. The in vitro studies demonstrate LYT-210's ability to induce cell death in these immune-suppressive cells while sparing vital T cells. This suggests potential for LYT-210 as a standalone treatment or in combination with other therapies, addressing several aggressive solid tumors and improving patient outcomes.

PureTech Health plc (Nasdaq: PRTC) has announced that its management team will present at two upcoming virtual investor conferences. The first is the 19th Annual Virtual Needham Healthcare Conference on April 12, 2021, featuring CFO George Farmer at 11:45 AM EDT. The second is a Fireside Chat with Liberum on April 28, 2021, with President Bharatt Chowrira and CFO George Farmer at 11:00 AM EDT. PureTech is focused on developing medicines for severe diseases and has a significant pipeline of 24 therapeutic candidates.

PureTech Health (Nasdaq: PRTC) announced that its Founded Entity, Akili Interactive, is collaborating with Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Vanderbilt University Medical Center to evaluate AKL-T01 as a treatment for cognitive dysfunction in COVID-19 survivors, commonly known as 'COVID brain fog'. The studies will investigate AKL-T01's effect on cognitive functioning through two randomized, controlled trials. With no current approved treatments for this condition, the studies aim to start recruitment next month, addressing a significant unmet medical need.

PureTech Health (Nasdaq: PRTC) notes the publication of data from the STARS Adjunct study by its Founded Entity, Akili Interactive, which evaluated the impact of EndeavorRx (AKL-T01) on ADHD symptoms in children. The study showed statistically significant improvements in all endpoints, marked by enhancements in daily life as rated by parents and clinicians. The results, published in Nature Digital Medicine, support previous FDA data leading to EndeavorRx's approval in June 2020, highlighting the potential of digital therapeutics in ADHD treatment.

PureTech Health (Nasdaq: PRTC, LSE: PRTC) announces the retirement of Chief Operating Officer Stephen Muniz, effective May 17, 2021. Bharatt Chowrira, President and Chief of Business and Strategy, will take over Muniz's responsibilities. CEO Daphne Zohar praised Muniz's contributions during his 13-year tenure, emphasizing his role in building a strong operations and legal team. PureTech focuses on developing innovative therapies for severe diseases, with a pipeline of 24 therapeutics, including two with FDA clearance.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) will release its annual report and financial results on April 15, 2021, covering the fiscal year ending December 31, 2020. This report will detail the company's financial status, including cash balances for Q1 2021, and offer insights into its Wholly Owned Pipeline and Founded Entities as well as its environmental, social, and governance (ESG) practices. A conference call for analysts is scheduled for the same day at 9:00 AM EDT, with a live webcast available on the company's investor website.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced that Chief Financial Officer George Farmer, Ph.D., will present at the Barclays Global Healthcare Conference on March 10th at 10:20 AM EST. A webcast of the presentation will be available on the company's investor relations page. PureTech focuses on developing innovative medicines for critical diseases, boasting a pipeline of 24 products, including two that received FDA clearance and European marketing authorization. The company leverages unique insights into the brain, immune, and gut systems to drive its research and development efforts.

PureTech Health (NASDAQ: PRTC) notes the announcement from its Founded Entity, Karuna Therapeutics (NASDAQ: KRTX), regarding the pricing of its public offering. Karuna will offer 2,083,334 shares at $120.00 per share, aiming for gross proceeds of approximately $250 million. An additional 312,500 shares may be purchased by underwriters within 30 days. The offering is expected to close around March 4, 2021. Goldman Sachs and J.P. Morgan are the joint book-running managers for this offering.